Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells

References

• Biasco G, Pantaleo MA, Casadei S. Treatment of brain metastases of malignant melanoma with temozolomide. N Engl J Med 2001; 345: 621–2; PMID:11529230; http://dx.doi.org/10.1056/NEJM200108233450817
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158–66; PMID:10623706
   PubMed Web of Science ®Google Scholar
• Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, Matthews S, Eisenhauer E. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 2006; 17: 952–6; PMID:16565212; http://dx.doi.org/10.1093/annonc/mdl056
   PubMed Web of Science ®Google Scholar
• van Brussel JP, Busstra MB, Lang MS, Catsburg T, Schroder FH, Mickisch GH. A phase II study of temozolomide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2000; 45: 509–12; PMID:10854140; http://dx.doi.org/10.1007/s002800051027
   PubMed Web of Science ®Google Scholar
• Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science 2001; 291: 1284–9; PMID:11181991; http://dx.doi.org/10.1126/science.1056154
   PubMed Web of Science ®Google Scholar
• Clemons M, Kelly J, Watson AJ, Howell A, McElhinney RS, McMurry TB, Margison GP. O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts. Br J Cancer 2005; 93: 1152–6; PMID:16278661; http://dx.doi.org/10.1038/sj.bjc.6602833
   PubMed Web of Science ®Google Scholar
• Sobol RW, Wilson SH. Mammalian DNA beta-polymerase in base excision repair of alkylation damage. Prog Nucleic Acid Res Mol Biol 2001; 68: 57–74; PMID:11554313; http://dx.doi.org/10.1016/S0079-6603(01)68090-5
   PubMed Web of Science ®Google Scholar
• Tentori L, Graziani G. Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med Chem 2002; 9: 1285–301; PMID:12052167; http://dx.doi.org/10.2174/0929867023369916
   PubMed Web of Science ®Google Scholar
• Lindahl T, Wood RD. Quality control by DNA repair. Science 1999; 286: 1897–905; PMID:10583946; http://dx.doi.org/10.1126/science.286.5446.1897
   PubMed Web of Science ®Google Scholar
• Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005; 65: 6394–400; PMID:16024643; http://dx.doi.org/10.1158/0008-5472.CAN-05-0715
   PubMed Web of Science ®Google Scholar
• Yan L, Bulgar A, Miao Y, Mahajan V, Donze JR, Gerson SL, Liu L. Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIalpha. Clin Cancer Res 2007; 13: 1532–9; PMID:17332299; http://dx.doi.org/10.1158/1078-0432.CCR-06-1595
   PubMed Web of Science ®Google Scholar
• Rinne M, Caldwell D, Kelley MR. Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Mol Cancer Ther 2004; 3: 955–67; PMID:15299078
   PubMed Web of Science ®Google Scholar
• Liu L, Yan L, Donze JR, Gerson SL. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Mol Cancer Ther 2003; 2: 1061–6; PMID:14578471
   PubMed Web of Science ®Google Scholar
• Stachelek GC, Dalal S, Donigan KA, Campisi Hegan D, Sweasy JB, Glazer PM. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation. Cancer Res; 70: 409–17; PMID:20028873; http://dx.doi.org/10.1158/0008-5472.CAN-09-1353
   PubMed Web of Science ®Google Scholar
• Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003; 9: 5370–9; PMID:14614022
   PubMed Web of Science ®Google Scholar
• Mortusewicz O, Ame JC, Schreiber V, Leonhardt H. Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res 2007; 35: 7665–75; PMID:17982172; http://dx.doi.org/10.1093/nar/gkm933
   PubMed Web of Science ®Google Scholar
• Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007; 13: 1383–8; PMID:17332279; http://dx.doi.org/10.1158/1078-0432.CCR-06-2260
   PubMed Web of Science ®Google Scholar
• Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, Li H, Salzman AL, Dolan ME, Modrich P, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005; 4: 1364–8; PMID:16170028; http://dx.doi.org/10.1158/1535-7163.MCT-05-0128
   PubMed Web of Science ®Google Scholar
• Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123–34; PMID:19553641; http://dx.doi.org/10.1056/NEJMoa0900212
   PubMed Web of Science ®Google Scholar
• Krishnamurthy N, Ngam CR, Berdis AJ, Montano MM. The exonuclease activity of hPMC2 is required for transcriptional regulation of the QR gene and repair of estrogen-induced abasic sites. Oncogene 2011; 30: 4731–9; PMID:21602889; http://dx.doi.org/10.1038/onc.2011.186
   PubMed Web of Science ®Google Scholar
• Sripathy SP, Chaplin LJ, Gaikwad NW, Rogan EG, Montano MM. hPMC2 is required for recruiting an ERbeta coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen. Oncogene 2008; 27: 6376–84; PMID:18663360; http://dx.doi.org/10.1038/onc.2008.235
   PubMed Web of Science ®Google Scholar
• Trivedi RN, Wang XH, Jelezcova E, Goellner EM, Tang JB, Sobol RW. Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. Mol Pharmacol 2008; 74: 505–16; PMID:18477668; http://dx.doi.org/10.1124/mol.108.045112
   PubMed Web of Science ®Google Scholar
• Patil R, Portilla-Arias J, Ding H, Inoue S, Konda B, Hu J, Wawrowsky KA, Shin PK, Black KL, Holler E, et al. Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(beta-L-malic acid). Pharm Res 2010; 27: 2317–29; PMID:20387095; http://dx.doi.org/10.1007/s11095-010-0091-0
   PubMed Web of Science ®Google Scholar
• Nakamura J, Walker VE, Upton PB, Chiang SY, Kow YW, Swenberg JA. Highly sensitive apurinic/apyrimidinic site assay can detect spontaneous and chemically induced depurination under physiological conditions. Cancer Res 1998; 58: 222–5; PMID:9443396
   PubMed Web of Science ®Google Scholar
• Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res 2007; 13: 260–7; PMID:17200364; http://dx.doi.org/10.1158/1078-0432.CCR-06-1920
   PubMed Web of Science ®Google Scholar
• Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin Cancer Res 1999; 5: 2908–17; PMID:10537360
   PubMed Web of Science ®Google Scholar
• Jacot W, Gerlotto-Borne MC, Thezenas S, Pouderoux S, Poujol S, About M, Romieu G. Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study. BMC Cancer 2010; 10: 257; PMID:20525352; http://dx.doi.org/10.1186/1471-2407-10-257
   PubMed Web of Science ®Google Scholar
• Weydert CJ, Zhang Y, Sun W, Waugh TA, Teoh ML, Andringa KK, Aykin-Burns N, Spitz DR, Smith BJ, Oberley LW. Increased oxidative stress created by adenoviral MnSOD or CuZnSOD plus BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) inhibits breast cancer cell growth. Free Radic Biol Med 2008; 44: 856–67; PMID:18155673; http://dx.doi.org/10.1016/j.freeradbiomed.2007.11.009
   PubMed Web of Science ®Google Scholar
• Alarcon K, Demeunynck M, Lhomme J, Carrez D, Croisy A. Potentiation of BCNU cytotoxicity by molecules targeting abasic lesions in DNA. Bioorg Med Chem 2001; 9: 1901–10; PMID:11425593; http://dx.doi.org/10.1016/S0968-0896(01)00097-9
   PubMed Web of Science ®Google Scholar
• Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88: 1346–60; PMID:8827012; http://dx.doi.org/10.1093/jnci/88.19.1346
   PubMed Web of Science ®Google Scholar
• Liuzzi M, Talpaert-Borle M. A new approach to the study of the base-excision repair pathway using methoxyamine. J Biol Chem 1985; 260: 5252–8; PMID:2580833
   PubMed Web of Science ®Google Scholar
• Rosa S, Fortini P, Karran P, Bignami M, Dogliotti E. Processing in vitro of an abasic site reacted with methoxyamine: a new assay for the detection of abasic sites formed in vivo. Nucleic Acids Res 1991; 19: 5569–74; PMID:1719478; http://dx.doi.org/10.1093/nar/19.20.5569
   PubMed Web of Science ®Google Scholar
• Atamna H, Cheung I, Ames BN. A method for detecting abasic sites in living cells: age-dependent changes in base excision repair. Proc Natl Acad Sci U S A 2000; 97: 686–91; PMID:10639140; http://dx.doi.org/10.1073/pnas.97.2.686
   PubMed Web of Science ®Google Scholar
• Wilson DM 3rd, Takeshita M, Grollman AP, Demple B. Incision activity of human apurinic endonuclease (Ape) at abasic site analogs in DNA. J Biol Chem 1995; 270: 16002–7; PMID:7608159; http://dx.doi.org/10.1074/jbc.270.27.16002
   PubMed Web of Science ®Google Scholar
• Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273: 5858–68; PMID:9488723; http://dx.doi.org/10.1074/jbc.273.10.5858
   PubMed Web of Science ®Google Scholar
• Dinnes J, Cave C, Huang S, Milne R. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 2002; 86: 501–5; PMID:11870527; http://dx.doi.org/10.1038/sj.bjc.6600135
   PubMed Web of Science ®Google Scholar
• Liu L, Nakatsuru Y, Gerson SL. Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res 2002; 8: 2985–91; PMID:12231545
   PubMed Web of Science ®Google Scholar
• Yan L, Donze JR, Liu L. Inactivated MGMT by O6-benzylguanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU. Oncogene 2005; 24: 2175–83; PMID:15735757; http://dx.doi.org/10.1038/sj.onc.1208250
   PubMed Web of Science ®Google Scholar
• Wood RD. DNA repair in eukaryotes. Annu Rev Biochem 1996; 65: 135–67; PMID:8811177; http://dx.doi.org/10.1146/annurev.bi.65.070196.001031
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74–108; PMID:15761078; http://dx.doi.org/10.3322/canjclin.55.2.74
   PubMed Web of Science ®Google Scholar
• Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol 2010; 28: 2966–73; PMID:20458051; http://dx.doi.org/10.1200/JCO.2009.25.9549
   PubMed Web of Science ®Google Scholar
• Montano MM, Katzenellenbogen BS. The quinone reductase gene: a unique estrogen receptor-regulated gene that is activated by antiestrogens. Proc Natl Acad Sci U S A 1997; 94: 2581–6; PMID:9122238; http://dx.doi.org/10.1073/pnas.94.6.2581
   PubMed Web of Science ®Google Scholar
• Ogba N, Chaplin L, Doughman YQ, Fujinaga K, Montano MM. HEXIM1 regulates E2/ERα-mediated expression of Cyclin D1 in mammary cells via modulation of P-TEFb. Cancer Research 2008; 68: 7015–24; PMID:18757415; http://dx.doi.org/10.1158/0008-5472.CAN-08-0814
   PubMed Web of Science ®Google Scholar
• Ketchart W, Ogba N, Kresak A, Albert JM, Pink JJ, Montano MM. HEXIM1 is a critical determinant of the response to tamoxifen. Oncogene 2011; 30: 3563–9; PMID:21423213; http://dx.doi.org/10.1038/onc.2011.76
   PubMed Web of Science ®Google Scholar